We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
The interplay between innate immunity & genetic risk factors in Alzheimer’s disease
Product News

The interplay between innate immunity & genetic risk factors in Alzheimer’s disease

The interplay between innate immunity & genetic risk factors in Alzheimer’s disease
Product News

The interplay between innate immunity & genetic risk factors in Alzheimer’s disease


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "The interplay between innate immunity & genetic risk factors in Alzheimer’s disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genetic mutations and variants play an important role in increasing the risk of developing inherited forms of Alzheimer’s disease (AD).


A recent study has highlighted the connection between three known genetic risk factors (TREM2, APOE and APOJ) linked to AD (Yeh et al., Neuron 2016).


Trem2 is a transmembrane glycoprotein expressed on the surface of microglia, and acts as a sensor for a distinct set of lipoproteins and apolipoproteins. TREM2 was shown to interact with APOE and APOJ, which are apolipoproteins capable of binding to amyloid beta (Aβ). This interaction helps facilitate the uptake and degradation of Aβ by the microglia. Interestingly, TREM2 AD variants demonstrate reduced ability to bind Aβ-apolipoprotein complexes.


These findings underscore the involvement of the innate immune cells such as microglia in the clearance of Aβ aggregates, and their dysfunction as a predisposing risk factor for developing late onset AD.


BioLegend
Learn more about BioLegend’s highly specific antibodies for TREM2, APOE, APOJ and related proteins


BioLegend


Advertisement